logo

Synlogic Inc (SYBX)



Trade SYBX now with
  Date
  Headline
9/20/2021 6:33:14 AM Synlogic Announces Positive Phase 2 Data Evaluating Both SYNB1618 And SYNB1934 For Phenylketonuria
9/10/2021 10:32:17 AM Synlogic Presents Data On SYNB8802 For Enteric Hyperoxaluria At American Urological Association Annual Meeting
8/12/2021 6:34:05 AM Synlogic Q2 Net $14.5 Mln Vs. Net Loss $15.5 Mln Last Year
7/15/2021 6:33:59 AM Synlogic Begins Phase 1 Study Of SYNB1934 For Phenylketonuria
6/17/2021 7:39:45 AM Synlogic Enters Research Collaboration Agreement With Roche
5/13/2021 6:40:42 AM Synlogic Q1 Consolidated Net Loss $15.0 Mln Or $0.36/Shr Vs Loss $15.8 Mln Or $0.46/Shr Last Year
4/16/2021 6:01:37 AM Synlogic Prices Public Offering Of 10 Mln Shares At $3/Shr
4/13/2021 9:24:19 AM Synlogic Presents Data Demonstrating Activity Of Solid Oral Formulation Of SYNB1618
3/25/2021 6:40:22 AM Synlogic Q4 Net Loss $14.6 Mln Or $0.39/Shr Vs Loss Of $12.8 Mln Or $0.37/Shr Last Year
3/8/2021 7:19:18 AM Synlogic Promotes Caroline Kurtz To Chief Development Officer
12/14/2020 6:05:48 AM Synlogic Says SYNB1891 Advanced Into Combination Therapy Stage Of The Phase 1 Trial
12/9/2020 6:31:26 AM Synlogic Appoints Michael Heffernan To Board